A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Trial Profile

A Phase IIb, placebo-controlled 13-week, study of THX-TS01 for the treatment of Tourette Syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs THX-110 (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Therapix Biosciences
  • Most Recent Events

    • 09 Nov 2017 According to a Therapix Biosciences media release, this study is anticipated to be conducted exclusively at the Hannover Medical School in Germany and the Company currently anticipates submitting the Investigational Medicinal Product Dossier (IMPD) for this trial by the end of 2017.
    • 10 Aug 2017 According to a Therapix Biosciences media release, the company is planning conduct this trial at the Hannover Medical School, Germany. And assessing the option to conduct a study in the United States as well. Decision about USA location will be given within a few weeks.
    • 15 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top